drugset / Trial / NCT00729495

Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib

NCT00729495

Phase 1 Completed 80 enrolled POZEN AstraZeneca · collab
RandomizedSingle-groupOpen-label

Summary

Phase I study designed to test the hypothesis that overencapsulated celecoxib 200 mg qd is bioequivalent to commercial celecoxib 200 mg qd. Approximately 90 healthy volunteers will be randomized to yield approximately 80 completers. The study is an open label, randomized, 2-way crossover with single dosing followed by a 7-day washout period between treatment arms

Timeline

Start
2008-07
Primary completion
2008-08
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg Oral

Indications

No indication recorded.